IN8bio announces INB-619, a novel γδ T cell therapy platform targeting CD19, showing promise in B cell depletion with reduced side effects. IN8bio, Inc. has announced the launch of its innovative γδ T ...
Nearly 600 cell lines commonly used in biomedical research today are misidentified or cross-contaminated, according to a recent paper and several additional studies. One estimates that nearly 33,000 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback